BioTime Announces $1.9 Million Grant for Continued Development of OpRegen® for Dry-AMD
BioTime, Inc. (NYSE American: BTX), a clinical-stage biotechnology company focused on degenerative diseases, has been awarded a new grant for 2018 of up to 6.9 million Israeli New Shekels (approximately $1.9 million) from the Israel Innovation Authority (the “IIA”). The grant provides funding for the continued development of OpRegen®, and to date the IIA has provided annual grants totaling over $13 million.
OpRegen® is currently in a Phase I/IIa clinical study, which in March 2018 received authorization from the Data Safety Monitoring Board (DSMB) to move forward with enrollment of cohort 4. The DSMB approval was based on the safety observed throughout the first three cohorts. Safety will remain the primary focus of cohort 4. The fourth cohort will include better vision patients than the previous three cohorts. These better vision patients will likely be in earlier stages of the disease and allow for a wide range of preliminary functional assessment measurements. These earlier stage patients will likely be the target patient population for this therapy and BioTime expects to share initial data from cohort 4 in the coming months.
“The IIA’s continued support is encouraging and shows their commitment and confidence in our ability to continue the development of OpRegen, our lead cell replacement program,” said Adi Mohanty, co-Chief Executive Officer of BioTime.
About OpRegen ®
OpRegen®, which is being studied for the treatment of the dry form of AMD, consists of a suspension of retinal pigment epithelial (RPE) cells that are delivered subretinally during a simple intraocular injection. RPE cells are essential components of the back lining of the retina, and function to help nourish the retina including photoreceptors. A proprietary process that drives the differentiation of human pluripotent stem cells is used to generate high purity OpRegen® RPE cells. OpRegen® RPE cells are also “xeno-free,” meaning that no animal products are used at any point in the derivation and production process. The avoidance of the use of animal products eliminates some potential safety concerns. Preclinical studies in rats have shown that following a single subretinal injection of OpRegen®, the cells can rapidly organize into its natural monolayer structure in the subretinal space and survive throughout the lifetime of the animal. OpRegen® is designed to be an “off-the-shelf” allogeneic (non-patient specific) product. Unlike treatments that require multiple, frequent injections into the eye, it is expected that OpRegen® will be administered in a single procedure. OpRegen® was granted Fast Track designation from the FDA, which allows more frequent interactions with the agency, and eligibility for accelerated approval and priority review. OpRegen® is a registered trademark of Cell Cure Neurosciences Ltd., a majority-owned subsidiary of BioTime, Inc.
About BioTime, Inc.
BioTime is a clinical-stage biotechnology company focused on degenerative diseases. Its clinical programs are based on two platform technologies: cell replacement and cell/drug delivery. With its cell replacement platform, BioTime is producing new cells and tissues with its proprietary pluripotent cell technologies. These cells and tissues are developed to replace those that are either rendered dysfunctional or lost due to degenerative diseases or injuries. BioTime’s cell/drug delivery programs are based upon its proprietary HyStem® cell and drug delivery matrix technology. HyStem® was designed, in part, to provide for the transfer, retention and/or engraftment of cellular replacement therapies. BioTime’s lead cell delivery clinical program is Renevia®, which consists of HyStem® combined with the patient's own adipose (fat) progenitor cells. Renevia® met its primary endpoint in an EU pivotal clinical trial for the treatment of facial lipoatrophy in HIV patients in 2017. BioTime has submitted Renevia® for CE Mark approval in the EU. There were no device related serious adverse events reported to date. BioTime’s lead cell replacement product candidate is OpRegen®, a retinal pigment epithelium transplant therapy, which is in a Phase I/IIa multicenter clinical trial for the treatment of dry age-related macular degeneration, the leading cause of blindness in developing countries. There were no unexpected serious adverse events reported to date. BioTime also has significant equity holdings in two publicly traded companies, Asterias Biotherapeutics, Inc. (NYSE American: AST) and OncoCyte Corporation (NYSE American: OCX), and a private company, AgeX Therapeutics, Inc.
BioTime common stock is traded on the NYSE American and TASE under the symbol BTX. For more information, please visit www.biotime.com or connect with the company on Twitter, LinkedIn, Facebook, YouTube, and Google+.
To receive ongoing BioTime corporate communications, please click on the following link to join the Company’s email alert list: http://news.biotime.com.
Certain statements contained in this release are “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Statements pertaining to product technology, clinical development, regulatory approval timelines, the success of potential cosmetic applications and potential opportunities for BioTime, Inc. and its subsidiaries, along with other statements about the future expectations, beliefs, goals, plans, or prospects expressed by management constitute forward-looking statements. Any statements that are not historical fact including, but not limited to statements that contain words such as “will,” “believes,” “plans,” “anticipates,” “expects,” “estimates” should also be considered forward-looking statements. Forward-looking statements involve risks and uncertainties, including, without limitation, risks inherent in the development and/or commercialization of potential products, uncertainty as to the results of clinical trials or regulatory approvals, need and ability to obtain future capital, and maintenance of intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements and as such should be evaluated together with the many uncertainties that affect the business of BioTime, Inc. and its subsidiaries, particularly those mentioned in the cautionary statements found in more detail in the “Risk Factors” section of BioTime’s Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q filed with the SEC (copies of which may be obtained at www.sec.gov). Subsequent events and developments may cause these forward-looking statements to change. BioTime specifically disclaims any obligation or intention to update or revise these forward-looking statements as a result of changed events or circumstances that occur after the date of this release, except as required by applicable law.
David Nakasone, 510-871-4188
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Innovid Bolsters Omni-channel Advertising Offering With Acquisition of Herolens18.9.2019 10:30:00 CEST | Press release
Innovid, the only independent omni-channel advertising and analytics platform built for television, today announced the acquisition of Herolens, an international advertising software company with expertise in display creative optimization technology. The acquisition expands Innovid’s existing global ad serving, dynamic creative personalization, and advanced measurement capabilities to include display formats alongside the company’s award-winning TV, video, and social solutions. Herolens is the leading creative management platform headquartered in Latin America, focused on delivering data-driven, dynamic and personalized creative on behalf of brands such as Coke, Renault, and Mercado Libre. Known for their flexible self-service, hybrid and full-service models, clients use Herolens as a central hub for digital asset management and dynamic creative customization, as well as display ad serving. “We’ve heard first-hand from our clients, the world’s largest TV spenders, the need to leverage
Smiths Detection opens office at Imperial College London’s White City campus18.9.2019 10:00:00 CEST | Press release
Global threat detection and security technologies company, Smiths Detection today announces the opening of an office at Imperial College London’s White City Campus within the I-Hub, with the intention of establishing a research and development (R&D) partnership between the two organizations. Imperial’s co-working facility in the I-Hub provides a space for Smiths Detection’s scientists and engineers to work more closely with the Colleges network of academics and researchers on cutting edge technologies for the defence and security markets. Smiths Detection’s new office adds to Imperial’s larger initiative to create a hub that focuses on security research, innovation and engagement led by the Institute of Security Science and Technology (ISST). Smiths Detection will be sitting amongst other innovators in the field who have already established offices at White City, including Airbus, Saab and DASA. “Imperial are looking to bring together some of the top innovators in the field to help add
Biedermann Motech to Introduce MOSS VRS® - The Next Generation Pedicle Screw Technology™ to the US Market18.9.2019 10:00:00 CEST | Press release
Biedermann Motech, the company that developed the world’s first polyaxial pedicle screw (MOSS® System) and pioneer in the spinal market for more than 30 years, today announced the further expansion of its product portfolio of advanced solutions for spinal surgery with the introduction of the MOSS VRS® Pedicle Screw System at the North American Spine Society (NASS) Annual Meeting in Chicago, IL, September 25-27, 2019. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190918005382/en/ Biedermann Motech to introduce MOSS VRS® - The Next Generation Pedicle Screw Technology™ to the US market at NASS 2019 in Chicago. Please join us at booth #2230 to learn more about the MOSS VRS System which allows the surgeon to lock the polyaxial angle of the pedicle screw at any angle, at any time during surgery, providing unmatched intraoperative options using a single, highly functional implant. (Photo: Business Wire) The MOSS VRS System feature
Thales Expands Advanced Access Management Capabilities for Authentication Customers to Take on Evolving Threat Landscape18.9.2019 09:56:00 CEST | Press release
From today, new adaptive authentication, single sign on and application visibility capabilities are available for Thales’ SafeNet Authentication Service customers with an automatic migration to SafeNet Trusted Access. With the enhanced access management capabilities of SafeNet Trusted Access, organizations have better control and visibility over their cloud estate with greater security, ease of use, and automated security capabilities to reduce the threats of identity-based attacks. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20190918005393/en/ (Photo: Thales) According to the 2019 Thales Access Management Index, the majority (97%) of IT leaders believe that cloud access management is necessary to continue their cloud adoption, and almost all (94%) have changed their security policies around access management due to a rise in security breaches in the last 12 months. With adaptive authentication and flexible access managemen
Janssen to Highlight Depth of Solid Tumour Portfolio with Multiple Data Presentations at ESMO 201918.9.2019 08:38:00 CEST | Press release
The Janssen Pharmaceutical Companies of Johnson & Johnson today announced multiple data presentations from its solid tumour portfolio, including key prostate cancer data, will be featured at the European Society for Medical Oncology (ESMO) 2019 Annual Congress, taking place 27th September to 1st October in Barcelona, Spain. Among Janssen’s 12 accepted abstracts is an oral presentation reporting overall survival from the Phase 3 SPARTAN study investigating the use of apalutamide in patients with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC); patient-reported outcomes from the Phase 3 TITAN study in patients with metastatic hormone-sensitive prostate cancer (mHSPC) demonstrating maintenance of overall health-related quality of life with apalutamide; and a late-breaking interim analysis from the Phase 2 GALAHAD study evaluating niraparib in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC) and biallelic DNA-repair gene defects
Tradeweb Launches Electronic Multi-Asset Package Trading on its Interest Rate Swaps Platform18.9.2019 08:00:00 CEST | Press release
Tradeweb Markets Inc. (Nasdaq: TW), a leading global operator of electronic marketplaces for rates, credit, equities and money markets, announced the launch of multi-asset package (MAP) trading on its global Interest Rate Swaps (IRS) platform. The first fully-electronic multi-asset package transaction using in-competition request-for-quote (RFQ) took place between Legal & General Investment Management (LGIM) and Bank of America Merrill Lynch. “Our MAP functionality is a clear demonstration of Tradeweb’s unique ability to enhance the trading experience for our clients, and connect the buy-side with deep liquidity pools across asset classes on a single electronic venue, and in this case a single trade,” said Lee Olesky, CEO of Tradeweb Markets. “Tradeweb’s strategic approach continues to be focused on building robust and efficient trading solutions that advance our markets globally.” The Tradeweb MAP functionality builds on the firm’s award-winning NPV (net present value) list trading to